vs

Side-by-side financial comparison of Globalstar, Inc. (GSAT) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $72.0M, roughly 1.0× Globalstar, Inc.). On growth, Globalstar, Inc. posted the faster year-over-year revenue change (17.6% vs -36.9%). Over the past eight quarters, Globalstar, Inc.'s revenue compounded faster (12.9% CAGR vs -34.4%).

Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

GSAT vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.0× larger
MED
$75.1M
$72.0M
GSAT
Growing faster (revenue YoY)
GSAT
GSAT
+54.5% gap
GSAT
17.6%
-36.9%
MED
Faster 2-yr revenue CAGR
GSAT
GSAT
Annualised
GSAT
12.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GSAT
GSAT
MED
MED
Revenue
$72.0M
$75.1M
Net Profit
$-11.6M
Gross Margin
69.4%
Operating Margin
-0.5%
-10.4%
Net Margin
-16.1%
Revenue YoY
17.6%
-36.9%
Net Profit YoY
76.9%
EPS (diluted)
$-0.11
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GSAT
GSAT
MED
MED
Q4 25
$72.0M
$75.1M
Q3 25
$73.8M
$89.4M
Q2 25
$67.1M
$105.6M
Q1 25
$60.0M
$115.7M
Q4 24
$61.2M
$119.0M
Q3 24
$72.3M
$140.2M
Q2 24
$60.4M
$168.6M
Q1 24
$56.5M
$174.7M
Net Profit
GSAT
GSAT
MED
MED
Q4 25
$-11.6M
Q3 25
$1.1M
$-2.3M
Q2 25
$19.2M
$2.5M
Q1 25
$-17.3M
$-772.0K
Q4 24
$-50.2M
Q3 24
$9.9M
$1.1M
Q2 24
$-9.7M
$-8.2M
Q1 24
$-13.2M
$8.3M
Gross Margin
GSAT
GSAT
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
GSAT
GSAT
MED
MED
Q4 25
-0.5%
-10.4%
Q3 25
13.8%
-4.6%
Q2 25
9.2%
-1.0%
Q1 25
-14.2%
-1.1%
Q4 24
-6.9%
0.6%
Q3 24
13.0%
1.5%
Q2 24
-2.4%
-4.7%
Q1 24
-8.3%
4.5%
Net Margin
GSAT
GSAT
MED
MED
Q4 25
-16.1%
Q3 25
1.5%
-2.5%
Q2 25
28.6%
2.3%
Q1 25
-28.9%
-0.7%
Q4 24
-82.1%
Q3 24
13.7%
0.8%
Q2 24
-16.0%
-4.8%
Q1 24
-23.4%
4.8%
EPS (diluted)
GSAT
GSAT
MED
MED
Q4 25
$-0.11
$-1.64
Q3 25
$-0.01
$-0.21
Q2 25
$0.13
$0.22
Q1 25
$-0.16
$-0.07
Q4 24
$-0.57
$0.08
Q3 24
$0.00
$0.10
Q2 24
$-0.01
$-0.75
Q1 24
$-0.01
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GSAT
GSAT
MED
MED
Cash + ST InvestmentsLiquidity on hand
$447.5M
$167.3M
Total DebtLower is stronger
$483.8M
Stockholders' EquityBook value
$355.7M
$198.9M
Total Assets
$2.3B
$248.0M
Debt / EquityLower = less leverage
1.36×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GSAT
GSAT
MED
MED
Q4 25
$447.5M
$167.3M
Q3 25
$346.3M
$173.5M
Q2 25
$308.2M
$162.7M
Q1 25
$241.4M
$164.6M
Q4 24
$391.2M
$162.3M
Q3 24
$51.9M
$170.0M
Q2 24
$64.3M
$163.5M
Q1 24
$59.3M
$156.4M
Total Debt
GSAT
GSAT
MED
MED
Q4 25
$483.8M
Q3 25
$508.6M
Q2 25
$491.5M
Q1 25
$502.7M
Q4 24
$511.4M
Q3 24
$394.4M
Q2 24
$393.1M
Q1 24
$398.7M
Stockholders' Equity
GSAT
GSAT
MED
MED
Q4 25
$355.7M
$198.9M
Q3 25
$364.8M
$214.7M
Q2 25
$360.9M
$216.0M
Q1 25
$344.3M
$211.0M
Q4 24
$358.9M
$210.1M
Q3 24
$394.1M
$207.3M
Q2 24
$383.0M
$205.3M
Q1 24
$377.1M
$211.0M
Total Assets
GSAT
GSAT
MED
MED
Q4 25
$2.3B
$248.0M
Q3 25
$2.2B
$268.2M
Q2 25
$1.9B
$269.3M
Q1 25
$1.7B
$280.0M
Q4 24
$1.7B
$284.2M
Q3 24
$917.6M
$291.2M
Q2 24
$926.2M
$293.5M
Q1 24
$917.0M
$302.8M
Debt / Equity
GSAT
GSAT
MED
MED
Q4 25
1.36×
Q3 25
1.39×
Q2 25
1.36×
Q1 25
1.46×
Q4 24
1.43×
Q3 24
1.00×
Q2 24
1.03×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GSAT
GSAT
MED
MED
Operating Cash FlowLast quarter
$175.9M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GSAT
GSAT
MED
MED
Q4 25
$175.9M
$-5.3M
Q3 25
$236.0M
$12.1M
Q2 25
$157.9M
$-3.4M
Q1 25
$51.9M
$3.4M
Q4 24
$340.7M
$-4.9M
Q3 24
$32.0M
$9.1M
Q2 24
$36.7M
$13.1M
Q1 24
$29.8M
$7.3M
Free Cash Flow
GSAT
GSAT
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
GSAT
GSAT
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
GSAT
GSAT
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
GSAT
GSAT
MED
MED
Q4 25
Q3 25
216.53×
Q2 25
8.22×
-1.36×
Q1 25
Q4 24
Q3 24
3.23×
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GSAT
GSAT

Services$67.4M94%
Products$4.6M6%

MED
MED

Segment breakdown not available.

Related Comparisons